SEC Form 4 research
| Issuer | NextCure, Inc. |
|---|---|
| Tickers | NXTC |
| Reporting owners | 42 |
| Officers and directors | 3 |
| Last public filing | 2026-10-27 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-10-27 | 2026-10-27 | ADAR1 Capital Management, LLC, Schneeberger Daniel | P | 3,553 | $5.1 | Not reported |
| 2026-10-27 | 2026-10-26 | ADAR1 Capital Management, LLC, Schneeberger Daniel | P | 1,672 | $5.03 | Not reported |
| 2026-10-27 | 2026-10-23 | ADAR1 Capital Management, LLC, Schneeberger Daniel | P | 5,626 | $4.83 | Not reported |
| 2026-08-12 | 2026-08-10 | Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., Ren Jinsheng, Simcere Pharmaceutical Group Ltd, Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Zaiming, Inc., Tang Renhong | S | 30,000 | $6.16 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.